ATE326238T1 - Mittel gegen myelome, welches zusammen mit antitumorwirkstoffen auf der basis von stickstoff-senfgasen verwendet werden kann - Google Patents

Mittel gegen myelome, welches zusammen mit antitumorwirkstoffen auf der basis von stickstoff-senfgasen verwendet werden kann

Info

Publication number
ATE326238T1
ATE326238T1 AT97928507T AT97928507T ATE326238T1 AT E326238 T1 ATE326238 T1 AT E326238T1 AT 97928507 T AT97928507 T AT 97928507T AT 97928507 T AT97928507 T AT 97928507T AT E326238 T1 ATE326238 T1 AT E326238T1
Authority
AT
Austria
Prior art keywords
nitrogen mustard
used together
agent against
myeloma
actives based
Prior art date
Application number
AT97928507T
Other languages
English (en)
Inventor
Akito Chugai Seiyaku Nakamura
Kenichi Chugai Seiyak Akamatsu
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE326238T1 publication Critical patent/ATE326238T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT97928507T 1996-06-27 1997-06-27 Mittel gegen myelome, welches zusammen mit antitumorwirkstoffen auf der basis von stickstoff-senfgasen verwendet werden kann ATE326238T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP16732596 1996-06-27

Publications (1)

Publication Number Publication Date
ATE326238T1 true ATE326238T1 (de) 2006-06-15

Family

ID=15847661

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97928507T ATE326238T1 (de) 1996-06-27 1997-06-27 Mittel gegen myelome, welches zusammen mit antitumorwirkstoffen auf der basis von stickstoff-senfgasen verwendet werden kann

Country Status (10)

Country Link
US (3) US6692742B1 (de)
EP (1) EP0923941B1 (de)
JP (1) JP3471195B2 (de)
AT (1) ATE326238T1 (de)
AU (1) AU3276297A (de)
DE (1) DE69735888T2 (de)
DK (1) DK0923941T3 (de)
ES (1) ES2263178T3 (de)
PT (1) PT923941E (de)
WO (1) WO1997049428A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3276297A (en) * 1996-06-27 1998-01-14 Chugai Seiyaku Kabushiki Kaisha Remedies for myeloma to be used together with nitrogen mustard antitumor agents
DK2011514T3 (da) 1997-03-21 2012-03-26 Chugai Pharmaceutical Co Ltd Forebyggende eller terapeutisk middel til sensibiliserede-T-celle-medierede sygdomme omfattende IL-6-antagonist som en aktiv bestanddel
SK287601B6 (sk) * 1998-09-14 2011-03-04 Board Of Regents, The University Of Texas System Použitie protilátky alebo jej fragmentu viažuceho antigén na výrobu farmaceutickej kompozície na liečenie mnohonásobného myelómu a na inhibíciu resorpcie kostí
US7618630B2 (en) * 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
DE60334678D1 (de) * 2002-02-14 2010-12-09 Chugai Pharmaceutical Co Ltd Antikörper enthaltende pharmazeutische lösungen
AU2003253681B2 (en) * 2002-06-24 2008-05-01 Research Development Foundation Treatment of human multiple myeloma by Curcumin
KR101119448B1 (ko) 2002-09-11 2012-03-15 추가이 세이야쿠 가부시키가이샤 단백질 정제 방법
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
CA2536380A1 (en) 2003-08-26 2005-02-26 Research Development Foundation Osteoclastogenesis inhibitors and uses thereof
ES2368741T3 (es) * 2004-02-25 2011-11-21 Dana-Farber Cancer Institute, Inc. Inhibidores del receptor 1 del factor de crecimiento de tipo insulina para inhibir el crecimiento de células tumorales.
JPWO2005090405A1 (ja) 2004-03-24 2008-04-17 中外製薬株式会社 インターロイキン−６受容体に対するヒト型化抗体のサブタイプ
US20080213399A1 (en) * 2005-02-03 2008-09-04 Topotarget Uk Limited Combination Therapies Using Hdac Inhibitors
US7872050B2 (en) * 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US8501818B2 (en) * 2005-03-14 2013-08-06 Ceptaris Therapeutics, Inc. Stabilized compositions of alkylating agents and methods of using same
US20110039943A1 (en) * 2005-03-14 2011-02-17 Robert Alonso Methods for treating skin disorders with topical nitrogen mustard compositions
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
KR101579218B1 (ko) * 2007-12-26 2015-12-21 바이오테스트 아게 Ｃｄ138 발현성 종양 세포에 대한 표적화를 개선시키기 위한 방법 및 물질
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2009120493A2 (en) 2008-03-27 2009-10-01 Yaupon Therapeutics, Inc Stabilized compositions of alkylating agents and methods of using same
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
ES2622366T3 (es) 2009-10-26 2017-07-06 F. Hoffmann-La Roche Ag Procedimiento para la producción de una inmunoglobulina glucosilada
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
RU2013126477A (ru) 2010-11-08 2014-12-20 Дженентек, Инк. Вводимые подкожно антитела против рецептора il-6
CN110711248A (zh) 2011-01-28 2020-01-21 赛诺菲生物技术公司 包含针对pcsk9的人抗体的药物组合物
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
AU2012372140B9 (en) 2011-12-08 2015-10-15 Biotest Ag Uses of immunoconjugates targeting CD138
BR112014032346A2 (pt) 2012-06-26 2017-06-27 Del Mar Pharmaceuticals métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes
AU2014251038A1 (en) 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
CA2913687C (en) 2013-07-04 2022-12-13 F. Hoffmann-La Roche Ag Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US10772956B2 (en) 2015-08-18 2020-09-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
WO2017147169A1 (en) 2016-02-22 2017-08-31 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites
WO2018170405A1 (en) 2017-03-17 2018-09-20 Ohio State Innovation Foundation Nanoparticles for delivery of chemopreventive agents
TWI860325B (zh) 2019-01-31 2024-11-01 法商賽諾菲生物技術公司 用於治療幼年原發性關節炎之組成物及方法
JP2022527972A (ja) 2019-04-02 2022-06-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 前悪性病変を有する患者において癌を予測及び予防する方法
AU2020261431A1 (en) 2019-04-24 2021-12-09 Regeneron Pharmaceuticals, Inc. Methods of diagnosis and treatment of rheumatoid arthritis
JP2022534794A (ja) 2019-06-04 2022-08-03 サノフィ・バイオテクノロジー 関節リウマチを有する対象における疼痛を治療するための組成物および方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
CA1275922C (en) * 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
JP2998976B2 (ja) * 1989-07-20 2000-01-17 忠三 岸本 ヒトインタ―ロイキン―６レセプターに対する抗体
US5795965A (en) * 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
US5882941A (en) * 1994-05-04 1999-03-16 Massachusette Institute Of Technology Programmable genotoxic agents and uses therefor
AU3276297A (en) * 1996-06-27 1998-01-14 Chugai Seiyaku Kabushiki Kaisha Remedies for myeloma to be used together with nitrogen mustard antitumor agents
US6635677B2 (en) * 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer

Also Published As

Publication number Publication date
AU3276297A (en) 1998-01-14
DE69735888D1 (de) 2006-06-22
US20020131967A1 (en) 2002-09-19
EP0923941A2 (de) 1999-06-23
DE69735888T2 (de) 2006-11-02
JP3471195B2 (ja) 2003-11-25
JPH1087510A (ja) 1998-04-07
US20040247621A1 (en) 2004-12-09
ES2263178T3 (es) 2006-12-01
DK0923941T3 (da) 2006-09-18
PT923941E (pt) 2006-09-29
EP0923941B1 (de) 2006-05-17
US7566453B2 (en) 2009-07-28
US7771723B2 (en) 2010-08-10
WO1997049428A1 (en) 1997-12-31
EP0923941A4 (de) 2001-12-05
US6692742B1 (en) 2004-02-17

Similar Documents

Publication Publication Date Title
ATE326238T1 (de) Mittel gegen myelome, welches zusammen mit antitumorwirkstoffen auf der basis von stickstoff-senfgasen verwendet werden kann
DE60121988D1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
FI956019A7 (fi) Eristettyjä peptidejä, jotka muodostavat komplekseja MHC-molekyyli HLA -C-klooni-10:n kanssa, ja niiden käyttö
DK0711140T3 (da) Antimykotisk opløsning til negle
BR9804500B1 (pt) derivado de amida, referida composição farmacêutica e agente terapêutico.
ATE486840T1 (de) Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür
TR199902396T2 (xx) Analjezik birle�ik.
CY1110462T1 (el) Θεραπεια της ηπατικης ινωσης με αντισωματα εναντιον της ενσωματινης (ιντεγκρινης) αλφα v βητα 6
PL357944A1 (en) Intradermal-penetration agents for topical local anesthetic administration
EA199700232A1 (ru) Дозирующий ингалятор для пропионата флутиказона
TR200002759T2 (tr) Bacak uyuşması sendromunun tedavisinde kabergolin kullanımı.
BR0002607A (pt) Composições lìquidas rapidamente absorvidas
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
TR199802351T2 (xx) Topikal kullanım için bir veya birden fazla lokal anestezik ve anti-vajinit maddeler ihtiva eden anti-vajinit bileşimi.
DK0909763T3 (da) Colchicin-derivater og terapeutisk anvendelse deraf
DE60141297D1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
DE69519368D1 (de) Neue antiandrogenen mitteln pharmazeutische präparate und verwendungen davon
DE69710423D1 (de) Orale pharmazeutische Zubereitung mit antipyretischer, analgetischer und entzündungshemmender Wirkung.
ES2152315T3 (es) Xamoneline tartrato.
DE69841260D1 (de) Bakterielle pheromone und deren verwendungen
DE69827017D1 (de) Kombinationen von endometrium schonenden gestagenen und endometrium atrophisierenden gestagenen mit estrogenen, bei der oralen empfängnisverhütung
TR200001075T2 (tr) Tiamfenikol ve diklofenak içeren bileşimler.
KR950014860U (ko) 가스렌지의 엘.피.지 와 엘.엔.지 가스겸용 메인노즐
朱宁文 Building Bridges in Burns Care
KR950008731U (ko) 전, 후로 이동되는 기관차 운전실용 의자

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0923941

Country of ref document: EP